David PS
Member
22 June 22 - Patients in the placebo group received a placebo for 12 months. The study found that 14 of 22 patients (63.6%) in the treatment arm became HPV-negative.
www.frontiersin.org
Frontiers | AHCC® Supplementation to Support Immune Function to Clear Persistent Human Papillomavirus Infections
ObjectiveTo determine the efficacy, safety, and durability of the use of AHCC supplementation for 6 months to support the host immune system to clear high-ri...
www.frontiersin.org
Last edited:
